What is Rasagiline, and what does its “SPC” usually mean?
“SPC” typically refers to the Summary of Product Characteristics, a regulatory document that describes a medicine’s approved use, dosing, contraindications, warnings, and how it’s to be used in practice. For rasagiline, the SPC is the main reference for instructions like who can use it, the exact dose, and key safety limits.
What is rasagiline used for (as stated in the SPC)?
Rasagiline is a medicine used in Parkinson’s disease. The SPC information generally covers approved indications such as treatment of Parkinson’s disease, including how it may be used alone or with levodopa depending on the specific wording in the approved product document.
How is rasagiline usually dosed according to the SPC?
Rasagiline dosing in SPC documents is typically specified as a once-daily dose (commonly 1 mg once daily in many jurisdictions), with instructions on starting and maximum daily dose, and guidance on what to do if treatment is interrupted. The SPC also specifies whether dose adjustments are recommended in certain situations (for example, in liver impairment).
Who should not take rasagiline (contraindications)?
SPCs for rasagiline usually list contraindications such as:
- Moderate to severe liver impairment, where relevant to that product’s regulatory decision
- Certain drug combinations that increase risk of serious interactions
What drug interactions are highlighted in the SPC?
Rasagiline’s SPC commonly warns about interactions with medicines that can raise serotonin or cause hypertensive crises. Interactions often addressed include:
- Other medicines that affect monoamine oxidase (MAO) activity
- Serotonergic drugs (risk of serotonin syndrome)
- Certain decongestants or sympathomimetics (risk of blood pressure problems), where listed
What side effects are commonly listed in the SPC?
SPCs generally include adverse reactions and frequency categories. For rasagiline, patient-relevant side effects often include:
- Movement-related symptoms (such as worsening dyskinesia) when combined with levodopa
- Falls and dizziness in some patients
- Nausea or abdominal complaints
- Headache and other neurologic symptoms
The exact list and frequencies depend on the specific SPC version for the marketed brand and country.
Are there special warnings about liver function?
Rasagiline SPC documents typically emphasize liver safety, often stating that rasagiline is not recommended or is contraindicated in clinically significant hepatic impairment, and that lighter impairment may require caution depending on the SPC.
Which country’s SPC do you mean?
SPCs differ by country/brand. If you tell me the country (or paste the link/text/title of the SPC you have), I can summarize the exact Rasagiline SPC sections: indication, dose, contraindications, interactions, and key safety warnings from that specific document.